Log in to search using one of your social media accounts:

 

Toll like receptor 2 (TLR2) signaling promotes apoptosis of premalignant hematopoietic stem and progenitor cells in a mouse model of myelodysplastic syndrome

The myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) disorders characterized by ineffective hematopoiesis and a high risk of leukemic transformation. The only curative treatment is stem cell transplantation; thus new therapies are needed. Multiple studies have shown a correlation between MDS and enhanced toll like receptor 2 (TLR2) signaling, suggesting this might contribute to disease pathogenesis. In fact, an inhibitory TLR2 antibody is currently in clinical trial for use in MDS (OPN-305, Opsona Therapeutics).
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research

Related Links:

Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to evaluate real-world evidence of treatment options for patients with HR-MDS/CMML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to evaluate real-world evidence of treatment options for patients with HR-MDS/CMML. Medline and Embase (January 2006 to May 2016) were searched, in addition to conference proceedings and treatment guideline reviews.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
Background: Studies of bone marrow cell clonal alterations in patients with Fanconi anemia (FA), a cancer-prone inherited bone marrow failure (BMF) syndrome, have focused on their role in progression from BMF to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The role of such alterations on patient outcomes after hematopoietic cell transplantation (HCT) is unknown.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Background: Azacitidine (Aza) and donor lymphocyte infusions (DLI) confer survival advantage with improved tolerability for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following allogenic stem cell transplantation (SCT).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Clinical Trials | Hematology | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Study | Transplants